Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Dassault Systèmes (OTC:DASTY) announced on Oct. 23, 2025 an expansion of its 10-plus-year collaboration between Medidata and Sanofi to accelerate clinical research and improve the patient journey.
The new enterprise agreement will deploy Medidata Experiences—patient, data, and study solutions with AI-embedded workflows—to streamline operations, improve data quality, support decentralized clinical trials, and provide strategic consulting and end-to-end operational support to Sanofi.
The expanded partnership aims to reduce silos, cut delays and costs, and speed therapies to market by combining Medidata platform capabilities with Sanofi’s clinical expertise.
Dassault Systèmes (OTC:DASTY) ha annunciato il 23 ottobre 2025 un'espansione della sua collaborazione decennale tra Medidata e Sanofi per accelerare la ricerca clinica e migliorare il percorso del paziente.
Il nuovo accordo aziendale implementerà Medidata Experiences—soluzioni per pazienti, dati e studi con workflow integrati da IA—per razionalizzare le operazioni, migliorare la qualità dei dati, supportare studi clinici decentralizzati e fornire consulenza strategica e supporto operativo end-to-end a Sanofi.
La partnership ampliata mira a ridurre i silos, tagliare ritardi e costi, e accelerare l'immissione di terapie sul mercato unendo le capacità della piattaforma Medidata all'expertise clinica di Sanofi.
Dassault Systèmes (OTC:DASTY) anunció el 23 de octubre de 2025 una ampliación de su colaboración de más de 10 años entre Medidata y Sanofi para acelerar la investigación clínica y mejorar el recorrido del paciente.
El nuevo acuerdo empresarial desplegará Medidata Experiences—soluciones para pacientes, datos y estudios con flujos de trabajo integrados con IA—para optimizar las operaciones, mejorar la calidad de los datos, apoyar ensayos clínicos descentralizados y proporcionar consultoría estratégica y soporte operativo de extremo a extremo a Sanofi.
La asociación expandida tiene como objetivo reducir silos, acortar retrasos y costos, y acelerar las terapias al mercado combinando las capacidades de la plataforma Medidata con la experiencia clínica de Sanofi.
Dassault Systèmes (OTC:DASTY)는 2025년 10월 23일에 Medidata와 Sanofi 간 10년 넘는 협력의 확장을 발표하여 임상 연구를 가속하고 환자 여정을 개선합니다.
새로운 엔터프라이즈 계약은 Medidata Experiences—AI가 내장된 워크플로를 갖춘 환자, 데이터 및 연구 솔루션—를 도입하여 운영을 간소화하고 데이터 품질을 향상시키며 분산 임상시험을 지원하고 Sanofi에 전략 컨설팅 및 엔드 투 엔드 운영 지원을 제공할 것입니다.
확대된 파트너십은 실로를 제거하고 지연과 비용을 줄이며 Medidata 플랫폼의 기능과 Sanofi의 임상 전문 지식을 결합하여 치료제를 시장에 속도시키는 것을 목표로 합니다.
Dassault Systèmes (OTC:DASTY) a annoncé le 23 octobre 2025 une extension de sa collaboration de plus de dix ans entre Medidata et Sanofi afin d'accélérer la recherche clinique et d'améliorer le parcours des patients.
Le nouvel accord d'entreprise déployera Medidata Experiences—des solutions pour les patients, les données et les études avec des flux de travail intégrés par IA—pour rationaliser les opérations, améliorer la qualité des données, soutenir les essais cliniques décentralisés et fournir des services de conseil stratégique et un support opérationnel de bout en bout à Sanofi.
Le partenariat élargi vise à réduire les silos, à diminuer les retards et les coûts, et à accélérer la mise sur le marché des thérapies en combinant les capacités de la plateforme Medidata avec l'expertise clinique de Sanofi.
Dassault Systèmes (OTC:DASTY) kündigte am 23. Oktober 2025 eine Erweiterung der über zehn Jahre laufenden Zusammenarbeit zwischen Medidata und Sanofi an, um die klinische Forschung zu beschleunigen und die Patientenreise zu verbessern.
Die neue Unternehmensvereinbarung wird Medidata Experiences – Patient-, Daten- und Studiendienste mit KI-gestützten Workflows – einsetzen, um Abläufe zu straffen, die Datenqualität zu verbessern, dezentralisierte klinische Studien zu unterstützen und Sanofi strategische Beratung sowie End-to-End-Betriebsunterstützung zu bieten.
Die erweiterte Partnerschaft zielt darauf ab, Silos abzubauen, Verzögerungen und Kosten zu senken und Therapien schneller auf den Markt zu bringen, indem die Funktionen der Medidata-Plattform mit der klinischen Expertise von Sanofi kombiniert werden.
Dassault Systèmes (OTC:DASTY) أعلنت في 23 أكتوبر 2025 عن توسيع تعاونها الذي يستمر لأكثر من عشر سنوات بين Medidata وSanofi لتسريع البحث السريري وتحسين تجربة المريض.
ستطبق الاتفاقية المؤسسية الجديدة Medidata Experiences — حلول للمرضى والبيانات والدراسات مع سير عمل مدمج بالذكاء الاصطناعي — لتبسيط العمليات، وتحسين جودة البيانات، ودعم التجارب السريرية الموزعة، وتقديم الاستشارات الاستراتيجية والدعم التشغيلي الشامل لـ Sanofi.
يهدف الشراكة الموسعة إلى تقليل العزلة والتقليل من التأخيرات والتكاليف، وتسريع وصول العلاجات إلى السوق من خلال دمج قدرات منصة Medidata مع الخبرة السريرية لـSanofi.
Dassault Systèmes (OTC:DASTY) 于 2025年10月23日 宣布扩大其与 Medidata 与 Sanofi 之间超过十年的合作，以加速临床研究并改善患者旅程。
新的企业级协议将部署 Medidata Experiences——具 AI 嵌入式工作流的患者、数据和研究解决方案——以简化运营、提升数据质量、支持分布式临床试验，并为 Sanofi 提供战略咨询和端到端的运营支持。
扩大的合作伙伴关系旨在消除信息孤岛、缩短延迟和成本，并通过整合 Medidata 平台能力与 Sanofi 的临床专业知识，将治疗药物尽快推向市场。
- Expanded 10-plus-year collaboration between Medidata and Sanofi
- New enterprise agreement to deploy Medidata Patient, Data, and Study Experiences
- Includes decentralized trials and end-to-end operational support to streamline research
- None.
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care
New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.
The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.
“Sanofi and Medidata have worked together for a decade within clinical research, including a collaboration in 2024,” said Gaelan Ritter, global head of digital clinical development, Sanofi. “With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.”
Sanofi will employ Medidata’s expertise and capabilities in decentralized clinical trials as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.
“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.”
To learn more about the Medidata Experiences, please visit here.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Contact:
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Sanofi PR
Sandrine Guendoul | sandrine.guendoul@sanofi.com
Evan Berland | evan.berland@sanofi.com
Léo Le Bourhis | leo.lebourhis@sanofi.com
Victor Rouault | victor.rouault@sanofi.com
Timothy Gilbert | timothy.gilbert@sanofi.com
Léa Ubaldi | lea.ubaldi@sanofi.com
Attachment
FAQ
What did Dassault Systèmes announce about Sanofi and Medidata on Oct. 23, 2025 (DASTY)?
How will the Medidata Experiences affect Sanofi clinical trials (DASTY)?
Does the Oct. 23, 2025 agreement with Sanofi include decentralized clinical trials (DASTY)?
Will Medidata provide operational support and consulting to Sanofi under the new deal (DASTY)?
What are the expected benefits for patients from the Sanofi–Medidata expansion (DASTY)?
Did Dassault Systèmes disclose financial terms or timelines for the Sanofi enterprise agreement (DASTY)?
